메뉴 건너뛰기




Volumn 18, Issue 7, 2011, Pages

An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients

Author keywords

entecavir; hepatitis B e antigen seroconversion; predictor; quantitative hepatitis B e antigen levels

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; POL PROTEIN;

EID: 79959608455     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01423.x     Document Type: Article
Times cited : (18)

References (39)
  • 3
    • 0023762809 scopus 로고
    • The development of cirrhosis in patients with chronic type B hepatitis: A prospective study
    • Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493-496.
    • (1988) Hepatology , vol.8 , pp. 493-496
    • Liaw, Y.F.1    Tai, D.I.2    Chu, C.M.3
  • 4
    • 0023771584 scopus 로고
    • Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B
    • Hoofnagle JH, Peters M, Mullen KD, et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318-1325.
    • (1988) Gastroenterology , vol.95 , pp. 1318-1325
    • Hoofnagle, J.H.1    Peters, M.2    Mullen, K.D.3
  • 5
    • 0024448926 scopus 로고
    • Which patients with chronic hepatitis B virus infection will respond to α-interferon therapy? A statistical analysis of predictive factors
    • Brook MG, Karayiannis P, Thomas HC,. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761-763. (Pubitemid 19270158)
    • (1989) Hepatology , vol.10 , Issue.5 , pp. 761-763
    • Brook, M.G.1    Karayiannis, P.2    Thomas, H.C.3
  • 7
    • 0026602420 scopus 로고
    • A controlled trial of interferon with or without prednisone priming for chronic hepatitis B
    • Lok AS, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-2097.
    • (1992) Gastroenterology , vol.102 , pp. 2091-2097
    • Lok, A.S.1    Wu, P.C.2    Lai, C.L.3
  • 8
    • 0036019518 scopus 로고    scopus 로고
    • Hepatitis B viral genotypes: Clinical relevance and molecular characteristics
    • Kao JH,. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002; 17: 643-650.
    • (2002) J Gastroenterol Hepatol , vol.17 , pp. 643-650
    • Kao, J.H.1
  • 10
    • 0027378724 scopus 로고
    • Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: A meta-analysis
    • Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J,. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-323. (Pubitemid 23319890)
    • (1993) Annals of Internal Medicine , vol.119 , Issue.4 , pp. 312-323
    • Wong, D.K.H.1    Cheung, A.M.2    O'Rourke, K.3    Naylor, C.D.4    Detsky, A.S.5    Heathcote, J.6
  • 11
    • 40849105240 scopus 로고    scopus 로고
    • Hepatitis B: Reflections on the current approach to antiviral therapy
    • Zoulim F, Perrillo R,. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008; 48: S2-S19.
    • (2008) J Hepatol , vol.48
    • Zoulim, F.1    Perrillo, R.2
  • 12
    • 70649104668 scopus 로고    scopus 로고
    • Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa
    • Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002-2009.
    • (2009) Gastroenterology , vol.137 , pp. 2002-2009
    • Buster, E.H.1    Hansen, B.E.2    Lau, G.K.3
  • 13
    • 0029806124 scopus 로고    scopus 로고
    • Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B
    • Hayashi PH, Beames MP, Kuhns MC, Hoofnagle JH, Di Bisceglie AM,. Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B. Am J Gastroenterol 1996; 91: 2323-2328. (Pubitemid 26383194)
    • (1996) American Journal of Gastroenterology , vol.91 , Issue.11 , pp. 2323-2328
    • Hayashi, P.H.1    Beames, M.P.2    Kuhns, M.C.3    Hoofnagle, J.H.4    Di Bisceglie, A.M.5
  • 14
    • 0031183753 scopus 로고    scopus 로고
    • Quantitative assessment of serum hepatitis B e antigen, IgM hepatitis B core antibody and HBV DNA in monitoring the response to treatment in patients with chronic hepatitis B
    • Bernard F, Raymond G, Willems B, Villeneuve JP,. Quantitative assessment of serum hepatitis B e antigen, IgM hepatitis B core antibody and HBV-DNA in monitoring the response to treatment in patients with chronic hepatitis B. J Viral Hepat 1997; 4: 265-272. (Pubitemid 127733433)
    • (1997) Journal of Viral Hepatitis , vol.4 , Issue.4 , pp. 265-272
    • Bernard, E.1    Raymond, G.2    Willems, B.3    Villeneuve, J.-P.4
  • 15
    • 0033816667 scopus 로고    scopus 로고
    • Interferon-alpha therapy in chronic hepatitis B: Early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy
    • Heijtink RA, Janssen HL, Hop WC, Osterhaus AD, Schalm SW,. Interferon-alpha therapy in chronic hepatitis B: early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy. J Viral Hepat 2000; 7: 382-386.
    • (2000) J Viral Hepat , vol.7 , pp. 382-386
    • Heijtink, R.A.1    Janssen, H.L.2    Hop, W.C.3    Osterhaus, A.D.4    Schalm, S.W.5
  • 16
    • 14844325741 scopus 로고    scopus 로고
    • Monitoring of HBeAg levels may help to predict the outcomes of lamivudine therapy for HBeAg positive chronic hepatitis B
    • DOI 10.1111/j.1365-2893.2005.00602.x
    • Park NH, Shin JW, Park JH, et al. Monitoring of HBeAg levels may help to predict the outcomes of lamivudine therapy for HBeAg positive chronic hepatitis B. J Viral Hepat 2005; 12: 216-221. (Pubitemid 40342182)
    • (2005) Journal of Viral Hepatitis , vol.12 , Issue.2 , pp. 216-221
    • Park, N.H.1    Shin, J.W.2    Park, J.H.3    Bang, S.-J.4    Kim, D.-H.5    Joo, K.R.6    Kim, D.H.7
  • 17
    • 0035172849 scopus 로고    scopus 로고
    • Rapid and specific genotyping system for hepatitis B virus corresponding to six major genotypes by PCR using type-specific primers
    • DOI 10.1128/JCM.39.1.362-364.2001
    • Natio H, Hayashi S, Abe K,. Rapid and specific genotyping system for hepatitis B virus corresponding to six major genotypes by PCR using type-specific primers. J Clin Microbiol 2001; 39: 362-364. (Pubitemid 32059621)
    • (2001) Journal of Clinical Microbiology , vol.39 , Issue.1 , pp. 362-364
    • Naito, H.1    Hayashi, S.2    Abe, K.3
  • 18
    • 18944387675 scopus 로고    scopus 로고
    • YMDD variants to HBV DNA polymerase gene: Rapid detection and clinicopathological analysis with long-term lamivudine therapy after liver transplantation
    • Pei F, Ning JY, You JF, Yang JP, Zheng J,. YMDD variants of HBV DNA polymerase gene: rapid detection and clinicopathological analysis with long-term lamivudine therapy after liver transplantation. World J Gastroenterol 2005; 11: 2714-2719. (Pubitemid 40704235)
    • (2005) World Journal of Gastroenterology , vol.11 , Issue.18 , pp. 2714-2719
    • Pei, F.1    Ning, J.-Y.2    You, J.-F.3    Yang, J.-P.4    Zheng, J.5
  • 20
    • 0015433262 scopus 로고
    • New specificities in Australia antigen positive sera distinct from the le Bouvier determinants
    • Magnius LO, Espmark JA,. New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants. J Immunol 1972; 109: 1017-1021.
    • (1972) J Immunol , vol.109 , pp. 1017-1021
    • Magnius, L.O.1    Espmark, J.A.2
  • 21
    • 0017761044 scopus 로고
    • Hepatitis B e antigen and infectivity of hepatitis B virus
    • Shikata T, Karasawa T, Abe K, et al. Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis 1977; 136: 571-576. (Pubitemid 8211390)
    • (1977) Journal of Infectious Diseases , vol.136 , Issue.4 , pp. 571-576
    • Shikata, T.1    Karasawa, T.2    Abe, K.3
  • 22
    • 0026683254 scopus 로고
    • Correlation between the prevalence of serum HBV DNA and immunoserologic HBV markers in the subjects with or without hepatitis
    • Luo KX, Zhou R, Liang ZS, Jiang S,. Correlation between the prevalence of serum HBV DNA and immunoserologic HBV markers in the subjects with or without hepatitis. Immunol Invest 1992; 21: 275-281.
    • (1992) Immunol Invest , vol.21 , pp. 275-281
    • Luo, K.X.1    Zhou, R.2    Liang, Z.S.3    Jiang, S.4
  • 24
    • 33744753396 scopus 로고    scopus 로고
    • Chronic hepatitis B: Current testing strategies
    • DOI 10.1016/j.cgh.2006.03.017, PII S1542356506002692
    • Gish RG, Locarnini SA,. Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol 2006; 4: 666-676. (Pubitemid 43825809)
    • (2006) Clinical Gastroenterology and Hepatology , vol.4 , Issue.6 , pp. 666-676
    • Gish, R.G.1    Locarnini, S.A.2
  • 25
    • 70350133508 scopus 로고    scopus 로고
    • Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naîve patients
    • Tenney DJ, Pokornowski KA, Rose RE, et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naîve patients. J Hepatol 2009; 50 (Suppl): S10.
    • (2009) J Hepatol , vol.50 , Issue.SUPPL.
    • Tenney, D.J.1    Pokornowski, K.A.2    Rose, R.E.3
  • 27
    • 84855801543 scopus 로고    scopus 로고
    • Five years of continuous entecavir for nucleoside-naîve HBeAg(+) chronic hepatitis B: Results from study ETV-901
    • Abstract No.: OP-48, Mar 20-24; Washington, DC. Available at: (accessed 2 June 2009)
    • Han SH, Chang TT, Chao YC, et al. Five years of continuous entecavir for nucleoside-naîve HBeAg(+) chronic hepatitis B: results from study ETV-901. Abstract No.: OP-48. Proceedings of the 13th International Symposium on Viral Hepatitis and Liver Disease; 2009 Mar 20-24; Washington, DC. Available at: (accessed 2 June 2009).
    • (2009) Proceedings of the 13th International Symposium on Viral Hepatitis and Liver Disease
    • Han, S.H.1    Chang, T.T.2    Chao, Y.C.3
  • 28
    • 79959590320 scopus 로고    scopus 로고
    • Bristol Myers-Squibb Available at: (accessed 1 June 2009)
    • Bristol Myers-Squibb. Entecavir AVDAC briefing document; 2005. Available at: (accessed 1 June 2009).
    • (2005) Entecavir AVDAC Briefing Document
  • 29
    • 77955981141 scopus 로고    scopus 로고
    • Entecavir induced HBV DNA suppression at 12 weeks in treatment-naive patients with chronic hepatitis B is a good predictive factor for virological response at 48 weeks
    • Lee HW, Kim HJ, Kim MH, et al. Entecavir induced HBV DNA suppression at 12 weeks in treatment-naive patients with chronic hepatitis B is a good predictive factor for virological response at 48 weeks. Hepatology 2008; 48: 741A.
    • (2008) Hepatology , vol.48
    • Lee, H.W.1    Kim, H.J.2    Kim, M.H.3
  • 30
    • 65849220728 scopus 로고    scopus 로고
    • Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48
    • Ma H, Ren JB, Li HY, et al. Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2007; 21: 102-104.
    • (2007) Zhonghua Shi Yan He Lin Chuang Bing du Xue Za Zhi , vol.21 , pp. 102-104
    • Ma, H.1    Ren, J.B.2    Li, H.Y.3
  • 32
    • 0033983436 scopus 로고    scopus 로고
    • Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: Performance of three commercial assays
    • DOI 10.1016/S0166-0934(99)00149-4, PII S0166093499001494
    • Pawlotsky JM, Bastie A, Hezode C, et al. Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays. J Virol Methods 2000; 85: 11-21. (Pubitemid 30068578)
    • (2000) Journal of Virological Methods , vol.85 , Issue.1-2 , pp. 11-21
    • Pawlotsky, J.-M.1    Bastie, A.2    Hezode, C.3    Lonjon, I.4    Darthuy, F.5    Remire, J.6    Dhumeaux, D.7
  • 33
    • 0036094158 scopus 로고    scopus 로고
    • Molecular diagnosis of viral hepatitis
    • Pawlotsky JM,. Molecular diagnosis of viral hepatitis. Gastroenterology 2002; 122: 1554-1568.
    • (2002) Gastroenterology , vol.122 , pp. 1554-1568
    • Pawlotsky, J.M.1
  • 34
    • 0027486290 scopus 로고
    • Monitoring of antiviral therapy with quantitative evaluation of HBeAg: A comparison with HBV DNA testing
    • DOI 10.1016/0270-9139(93)90216-A
    • Perrillo R, Mimms L, Schechtman K, Robbins D, Campbell C,. Monitoring of antiviral therapy with quantitative evaluation of HBeAg: a comparison with HBV DNA testing. Hepatology 1993; 18: 1306-1312. (Pubitemid 23348414)
    • (1993) Hepatology , vol.18 , Issue.6 , pp. 1306-1312
    • Perrillo, R.1    Mimms, L.2    Schechtman, K.3    Robbins, D.4    Campbell, C.5
  • 37
    • 33748305988 scopus 로고    scopus 로고
    • Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays
    • DOI 10.1016/j.antiviral.2006.05.006, PII S016635420600132X
    • Zhou T, Guo H, Guo J-T, Cuconati A, Mehta A, Block TM,. Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays. Antiviral Res 2006; 72: 116-124. (Pubitemid 44332566)
    • (2006) Antiviral Research , vol.72 , Issue.2 , pp. 116-124
    • Zhou, T.1    Guo, H.2    Guo, J.-T.3    Cuconati, A.4    Mehta, A.5    Block, T.M.6
  • 38
    • 70449673114 scopus 로고    scopus 로고
    • Simultaneous quantitation of serum HBV DNA and HBeAg can distinguish between slow and fast viral responses to antiviral therapy in patients with chronic hepatitis B
    • da Silva LC, Nova ML, Ono-Nita SK, et al. Simultaneous quantitation of serum HBV DNA and HBeAg can distinguish between slow and fast viral responses to antiviral therapy in patients with chronic hepatitis B. Rev Inst Med Trop Sao Paulo 2009; 51: 261-268.
    • (2009) Rev Inst Med Trop Sao Paulo , vol.51 , pp. 261-268
    • Da Silva, L.C.1    Nova, M.L.2    Ono-Nita, S.K.3
  • 39
    • 75449107726 scopus 로고    scopus 로고
    • Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B
    • Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-430.
    • (2010) Hepatology , vol.51 , pp. 422-430
    • Chang, T.T.1    Lai, C.L.2    Kew Yoon, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.